C9164 HCPCS Level II Code: Cantharidin for topical administration, 0.7%, single unit dose applicator (3.2 mg)
Medicare Coverage & Payment
- CMS short descriptor: Cantharidin top, applicator
- Medicare coverage: Special coverage instructions apply (CMS coverage code D)
- Pricing indicator: 53
- BETOS: O1E — Other drugs
- Last CMS action effective: April 1, 2024
- Terminated: March 31, 2024
Source: CMS HCPCS Level II release. Coverage codes indicate how Medicare treats the code, not whether a specific claim will be paid; payer policy and documentation still govern.
Code Set: Removed from the code set — not valid on or after April 1, 2024.
Contextual Map
Every relationship of C9164 in one view: hierarchy, official tabular instructions in both directions, clinical classification, risk adjustment, MS-DRG participation, index terms and change history — each edge carrying the CMS source it derives from.
Nearest codes (40)
- C9136 — Injection, factor viii, fc fusion protein, (recombinant), per i.u.[Sibling]— CMS HCPCS Level II code set
- C9137 — Injection, factor viii (antihemophilic factor, recombinant) pegylated, 1 i.u.[Sibling]— CMS HCPCS Level II code set
- C9138 — Injection, factor viii (antihemophilic factor, recombinant) (nuwiq), 1 i.u.[Sibling]— CMS HCPCS Level II code set
- C9139 — Injection, factor ix, albumin fusion protein (recombinant), idelvion, 1 i.u.[Sibling]— CMS HCPCS Level II code set
- C9140 — Injection, factor viii (antihemophilic factor, recombinant) (afstyla), 1 i.u.[Sibling]— CMS HCPCS Level II code set
- C9141 — Injection, factor viii, (antihemophilic factor, recombinant), pegylated-aucl (jivi), 1 i.u.[Sibling]— CMS HCPCS Level II code set
- C9142 — Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg[Sibling]— CMS HCPCS Level II code set
- C9143 — Cocaine hydrochloride nasal solution (numbrino), 1 mg[Sibling]— CMS HCPCS Level II code set
- and 32 more
Change history (2)
- April 1, 2024 — Removed from the code set [Change history]— CMS release files (code change ledger)
- and 1 more
Sources for this page
Codes, titles, notes, index terms and mappings on this page are transcribed from the datasets below. Relationships MedCoder computed and text MedCoder wrote are labelled where they appear.
- Code, descriptors, coverage and pricing attributes Official source data
- CMS HCPCS Alpha-Numeric (ANWEB) release — July 2026 quarterly update Release, file and checksum · Publisher’s page
- Change history and date-of-service validity Official source data
- CMS HCPCS quarterly update files, ingested into the change ledger Release, file and checksum · Publisher’s page
- Comparisons, relationships and the contextual map MedCoder structured relationship
- Computed by MedCoder from the tabular notes and tables above; every derived relationship is marked as derived where it appears
- Summary and FAQ answers MedCoder explanation
- Written by MedCoder to explain the sources above: drafted with AI assistance, checked by a person against the release files, and labelled as MedCoder text where it appears. Not official text.
Labels on this page: Official source data · MedCoder structured relationship · MedCoder explanation. How to read the labels · All data sources and release dates
Change history
- April 1, 2024Removed from the code setCantharidin for topical administration, 0.7%, single unit dose applicator (3.2 mg)
- January 1, 2024Added to the code setCantharidin for topical administration, 0.7%, single unit dose applicator (3.2 mg)
Nearest Codes in This Family
Official HCPCS Level II classifications closest to C9164 in its code family, with their registry titles.
- C9159 — Injection, prothrombin complex concentrate (human), balfaxar, per i.u. of factor ix activity
- C9160 — Injection, daxibotulinumtoxina-lanm, 1 unit
- C9161 — Injection, aflibercept hd, 1 mg
- C9162 — Injection, avacincaptad pegol, 0.1 mg
- C9163 — Injection, talquetamab-tgvs, 0.25 mg
- C9165 — Injection, elranatamab-bcmm, 1 mg
- C9166 — Injection, secukinumab, intravenous, 1 mg
- C9167 — Injection, adamts13, recombinant-krhn, 10 iu
- C9168 — Injection, mirikizumab-mrkz, 1 mg
- C9169 — Injection, nogapendekin alfa inbakicept-pmln, for intravesical use, 1 microgram